Vaxcyte (PCVX) Change in Acquisitions & Divestments (2021 - 2026)

Vaxcyte (PCVX) has reported Change in Acquisitions & Divestments for 6 consecutive years, with $340.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 22.32% year-over-year to $340.6 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 187.19% YoY), while the FY2025 annual figure was $1.5 billion, up 2186.68% from the prior year.
• Change in Acquisitions & Divestments fell to $340.6 million in Q1 2026 per PCVX's latest filing, from $348.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $853.8 million in Q3 2024 and bottomed at -$802.7 million in Q4 2024.
• Historically, Change in Acquisitions & Divestments has averaged $170.0 million across 5 years, with a median of $83.9 million in 2022.
• On a YoY basis, Change in Acquisitions & Divestments climbed as much as 13298.57% in 2024 and fell as far as 233.1% in 2024.
• Vaxcyte's Change in Acquisitions & Divestments stood at $158.2 million in 2022, then surged by 281.24% to $603.1 million in 2023, then plunged by 233.1% to -$802.7 million in 2024, then surged by 143.35% to $348.0 million in 2025, then slipped by 2.11% to $340.6 million in 2026.
• Business Quant data shows PCVX's Change in Acquisitions & Divestments at $340.6 million in Q1 2026, $348.0 million in Q4 2025, and $350.2 million in Q3 2025.